Novartis nears deal to buy U.S. biotech firm Medicines Co for about $7 billion: WSJ

Business

FILE PHOTO: Switzerland’s national flag flies in front of the logo of Swiss drugmaker Novartis in Basel, Switzerland, January 30, 2019. REUTERS/Arnd Wiegmann/File Photo

(Reuters) – Swiss drugmaker Novartis AG (NOVN.S) is nearing an agreement to acquire U.S. biotechnology firm The Medicines Co (MDCO.O) for about $7 billion, the Wall Street Journal reported on Saturday.

The deal, in which Novartis has agreed to pay $85 a share, could be announced this weekend, the Journal reported, citing people familiar with the matter.

Neither Novartis nor The Medicines Co were immediately available for comment on Saturday.

Reporting by Kanishka Singh in Bengaluru; editing by Jonathan Oatis

Products You May Like

Articles You May Like

Amazon’s new cloud boss inherits a business at crossroads over AI
Elon Musk’s SpaceX to Commission Two ESA Launches to Fill Gap Left by Russia
Nvidia crushes earnings expectations, charts continued AI dominance
Book review of Goddess of the River by Vaishnavi Patel
Hakeem Jeffries Tells The American People To Keep The Heat On Alito And Thomas